BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer BioNTech (Nasdaq: BNTX) will present late-stage lung cancer data at ELCC 2026 (March 25-28), highlighting updates on pumitamig, gotistobart and the HER3-targeted ADC BNT326/YL202. Key clinical notes include a reported 54% reduction in risk of death for gotistobart versus chemotherapy in stage 1 PRESERVE-003 and multiple China-based trial updates for pumitamig supporting ongoing global Phase 2/3 and Phase 3 programs.The portfolio now spans 16 ongoing lung cancer trials, including four pivotal Phase 3 studies and five novel-novel combination trials.

#BNTX BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

www.stocktitan.net/news/BNTX/bio-n-tech-cli...

⚠️ #BNTX BIONTECH ADRS SINK 19%, THE MOST INTRADAY SINCE APRIL 25

📢 Stocks Trending NOW: #NIO #ORCL #KSS #JOBY #BNTX #GSIW #RIVN #INKT #VTAK #CRSP

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update BioNTech (Nasdaq: BNTX) reported full year 2025 revenues of €2.87 billion, an IFRS net loss of €1.14 billion (adjusted net loss €117.1 million) and cash, cash equivalents and investments of €17.24 billion as of December 31, 2025.The company expects 2026 revenues of €2.0–2.3 billion, adjusted R&D of €2.2–2.5 billion and adjusted SG&A of €700–800 million. Co-founders will form an independent mRNA company with a management transition by end-2026. Multiple late-stage oncology readouts including pumitamig programs are planned for 2026.

#BNTX BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

www.stocktitan.net/news/BNTX/bio-n-tech-ann...

Is BioNTech SE (BNTX) A Good Stock To Buy Now? We came across a bullish thesis on BioNTech SE on Memyselfandi007's Substack. In this article, we will summarize the bulls' thesis on BNTX. BioNTech SE's share was trading at $103.80...

Bullish on $BNTX! BioNTech SE gains momentum, trading at $103.80. Is it a good buy now?
#BioNTech #BNTX #StockMarket #Investing

https://a777.lt/U9FHLT

Looking for FREE stock market news?

Check out Alpha Coverage: wealthwisedca.substack.com/p/alpha-cove...

#PL #AAPL #GOOGL #ORA #GOOG #GOOGL #BMNR #CRML #AUR #HUMN #KOID #BOTZ #AMD #QCLN #TAN #MP #GOOG #WMT #SHOP #W #GOOG #WMT #Kepler #SPY #TLT #GLD #SLV #UUP #BNTX #RGTI #MRNA #MSTR #BTC #Bitcoin

BioNTech Completes CureVac Acquisition, Expanding Its mRNA Platform BioNTech SE ( NASDAQ: BNTX) has completed its acquisition of CureVac N.V., closing its public exchange offer and moving toward full integration of the two mRNA

#BioNTech ( #BNTX) has closed its roughly $1.25 billion all‑stock acquisition of #CureVac, bringing in CureVac’s mRNA design, LNP delivery, and manufacturing assets to deepen BioNTech’s oncology‑focused mRNA platform.
prismmarketview.com/biontech-com...

BioNTech Achieves Minimum Condition in CureVac Exchange Offer BioNTech (Nasdaq: BNTX) announced that the minimum condition for its exchange offer for CureVac (Nasdaq: CVAC) has been satisfied after 184,071,410 CureVac shares (approximately 81.74% of issued and outstanding shares) were validly tendered before the initial period expired on Dec 3, 2025.All validly tendered shares have been accepted and closing conditions for the post-offer reorganization are satisfied. BioNTech will deliver BioNTech ADSs (or cash in lieu of fractional ADSs) to tendering holders. A subsequent offering period runs until 12:01 a.m. ET on Dec 18, 2025. Non-tendering holders will receive ADSs (or cash) via reorganization and generally face a 15% Dutch dividend withholding tax; non-tendering shares will cease to be tradable post-reorganization.

#BNTX BioNTech Achieves Minimum Condition in CureVac Exchange Offer

www.stocktitan.net/news/BNTX/bio-n-tech-ach...

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration BioNTech (Nasdaq: BNTX) announced key details and timing for its exchange offer for all outstanding CureVac shares (Nasdaq: CVAC).The Offer is set to expire at 9:00 a.m. Eastern Time on December 3, 2025; CureVac shareholders are advised to tender by 6:00 p.m. ET on December 2, 2025 due to operational deadlines. The announced Exchange Ratio is 0.05363 BioNTech ADS per CureVac share, based on a 10‑day VWAP of BioNTech ADS of $101.88 (ending November 25, 2025).At CureVac’s EGM on November 25, 2025, over 99.16% of votes cast approved the Offer‑related proposals. The Offer requires at least 80% valid tendered shares to close (may be reduced to 75% after four extensions). Non‑tendering holders who receive ADSs will generally face a 15% Dutch dividend withholding tax.

#BNTX BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

www.stocktitan.net/news/BNTX/bio-n-tech-sha...

Pfizer Looks to Sell Stake in BioNTech -- BBG

#PFE #BNTX

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stages Demonstrated encouraging anti-tumor activity and manageable safety profile of

#BNTX BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

www.stocktitan.net/news/BNTX/bio-n-tech-ann...

#BNTX #JPM #PFE #6b32b45c-31ae-4d22-99f7-af1e03547ec8 #investing

Origin | Interest | Match

#BNTX #PFE #82c2e505-d02e-42d2-8dd5-c45dff0a9d14 #investing

Origin | Interest | Match

BioNTech shares closed over 8% in trading Friday after announcing positive Phase 3 trial results for a breast cancer drug developed with Duality Biologics.

#BNTX #BioNTech #BNTXStock #BNTXNews #BNTXStockNews #BioNTechStock #BioNTechNews #BioNTechStockNews #DualityBio #BreastCancer #CancerResearch

Pfizer and BioNTech Share Positive Phase 3 Results For Their Updated COVID-19 Vaccine, Showing A Fourfold Increase In Antibody Levels And No New Safety Issues From 2025-2026 Formula

#PFE #BNTX

BBG: BioNTech Says Experimental Breast Cancer Drug Succeeded in Trial

#BNTX

Florida is set to become the first U.S. state to eliminate all vaccine requirements, including those for children in public schools.

#MRNA #BNTX #Moderna #BioNTech #MRNAStock #BNTXStock #ModernaStock #BioNTechStock #Florida #VaccineMandates #PublicHealth #JosephLadapo #FloridaNews #Vaccines

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 BioNTech (NASDAQ:BNTX) and Pfizer have received FDA approval for their LP.8.1-adapted monovalent COVID-19 vaccine COMIRNATY® for adults 65 and older, and individuals 5-64 years with high-risk conditions. The 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, selected based on FDA guidance to better match circulating strains.Pre-clinical data shows the vaccine generates improved immune responses against multiple SARS-CoV-2 sublineages, including XFG and NB.1.8.1, compared to previous JN.1 and KP.2-adapted versions. Immediate shipping will begin to ensure widespread availability across U.S. pharmacies, hospitals, and clinics.To date, 5 billion doses of the Pfizer-BioNTech COVID-19 vaccine have been distributed globally, maintaining a favorable safety and efficacy profile supported by extensive real-world evidence.

#BNTX Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

www.stocktitan.net/news/BNTX/pfizer-and-bio...

after earnings

#L Loews = 0%
#BNTX Biontech = +3%
#W Wayfair = +8%
#TSEM Tower Semiconductor = +5%
#TSN Tyson Foods = +4%
#ON ON Semiconductors = -4%

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update BioNTech (NASDAQ:BNTX) reported Q2 2025 financial results and significant strategic developments. The company recorded revenues of €260.8 million and a net loss of €386.6 million (€1.60 per share). Key highlights include a major collaboration with Bristol Myers Squibb for BNT327 development, featuring a $1.5 billion upfront payment and potential milestone payments up to $7.6 billion.The company maintains a strong financial position with €16.0 billion in cash and investments. BioNTech reaffirmed its 2025 revenue guidance of €1.7-2.2 billion. The company received approval for a new variant-adapted COVID-19 vaccine in Europe, with deliveries expected to begin in August 2025.Strategic developments include the announced acquisition of CureVac and advancement of oncology programs, particularly in pan-tumor treatments. R&D expenses were €509.1 million for Q2 2025, showing the company's continued investment in pipeline development.

#BNTX BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

www.stocktitan.net/news/BNTX/bio-n-tech-ann...

#PFE #BNTX #421877ba-8135-4e6e-a54d-02926ec93915 #investing

Origin | Interest | Match

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants 1 – compared to 2024-2025 COVID-19 vaccine formulations Upon authorization by the European Commission (EC), the

#BNTX Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

www.stocktitan.net/news/BNTX/pfizer-and-bio...

BioNTech CSO Exits After Driving $1B+ in Financing and Strategic Growth: Key Leadership Change Details Ryan Richardson departs after leading BioNTech's IPO, strategic acquisitions, and raising over $1B in capital. Learn about the transition plan and future strategy.

#BNTX BioNTech Announces Ryan Richardson to Step Down from the Management Board

www.stocktitan.net/news/BNTX/bio-n-tech-ann...

BioNTech to Acquire CureVac in $1.25 Billion Stock Deal to Expand mRNA Capabilities; CVAC Shares Surge 32% BioNTech (NASDAQ: BNTX) announced it will acquire all outstanding shares of CureVac (NASDAQ: CVAC) in an all-stock transaction valued at approximately $1.25 bil

#BNTX Expands mRNA Powerhouse with $1.25B CureVac Deal
BioNTech is set to acquire CureVac in a $1.25 billion all-stock transaction, accelerating its mRNA innovation pipeline.
#BioNTech

prismmarketview.com/biontech-to-...

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer BioNTech (BNTX) announced a strategic all-stock acquisition of CureVac in a deal valued at approximately $1.25 billion. Under the agreement, each CureVac share will be exchanged for $5.46 in BioNTech ADSs, representing a 55% premium to CureVac's three-month volume weighted average price. The acquisition aims to strengthen BioNTech's oncology strategy by combining both companies' mRNA capabilities in research, development, manufacturing, and commercialization of cancer immunotherapy candidates. The transaction, expected to close in 2025, has received unanimous approval from both companies' boards and support from CureVac's major shareholders, representing 50.08% of shares. Upon closing, CureVac shareholders will own between 4-6% of BioNTech, and CureVac's operating subsidiary will become wholly owned by BioNTech, including its Tübingen research and manufacturing site.

#BNTX BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

www.stocktitan.net/news/BNTX/bio-n-tech-ann...

BioNTech & Bristol Myers Ink $11.1B Cancer Drug Pact

#BNTX #BNTXStock #BNTXNews #BNTXStockNews #BMY #BMYStock #BMYNews #BMYStockNews #BioNTech #BioNTechStock #BioNTechNews #BioNTechStockNews #BristolMyersSquibb #BristolMyersSquibbStock #BristolMyersSquibbNews #BristolMyersSquibbStockNews #BristolMy

www.fool.com/investing/2025/06/02/why...

#BNTX #PFE #BMY #4bf6c48a-5b4d-46cb-8f63-75660326ca39 #investing

Result Details